T-Knife has emerged from stealth with $77.6m in series A funding to advance four potential cancer treatments into the clinic and open a US office.

UC Berkeley’s SiFive has raised $61m in series E funding from a consortium featuring OUP, SK Hynix, Western Digital, Qualcomm and Intel.

The CNS disease drug developer has raised funding in a GV-backed round just four months after it emerged from UT Southwestern with $30m.

Osage University Partners backed a round for Aerovate Therapeutics that will go to testing an inhaled version of the latter's pulmonary disease therapy.

Cigna and Kaiser Permanente have participated in a $50m series D round for Ginger, bringing the MIT spinout's total funding to more than $120m.

Osage University Partners-backed PMV has pushed its funding total to $236m as it further commercialises Princeton research stretching back to 1979.

Omega Therapeutics is firing up preclinical development of an epigenomic drug platform invented at Whitehead Institute and incubated by Flagship Pioneering.

Nura Bio is working on neuroprotective treatments that exploit discoveries made at OHSU and UT Southwestern.

Indigo Diabetes increased its total funding to $52.6m with a series B round backed by Imec.xpand and returning investor Qbic.

Forge is working on a gene therapy treatment invented at UPMC but has covered its bases by targeting viral vector production for third-party clients.